US Manufacturing’s AI Wake-Up Call: Bristol Myers Squibb’s Lone Factory Milestone

American Factories Lag in Adopting A.I. This Drugmaker Is an Exception. – Image for illustrative purposes only (Image credits: Pexels)

Devens, Massachusetts — A single American plant earned global acclaim for pioneering artificial intelligence in production this year, highlighting broader struggles in U.S. factories to keep pace with international rivals.[1][2] Bristol Myers Squibb’s facility here, focused on cancer-fighting biologics and cell therapies, joined the World Economic Forum’s elite Global Lighthouse Network as the only U.S. site among 23 newcomers.[3] The recognition underscores how targeted tech integration can transform complex drug manufacturing.

What Makes a Global Lighthouse?

The World Economic Forum, in partnership with McKinsey, annually identifies factories that master Fourth Industrial Revolution technologies like AI, IoT, and digital twins to drive real impact.[1] These “lighthouses” now number over 220 across more than 30 countries, spanning industries from automotive to pharmaceuticals. Sites must demonstrate scaled improvements in areas such as productivity, sustainability, and supply chain resilience.

In January 2026, the latest wave added 23 facilities, with Bristol Myers Squibb’s Devens plant standing out in the productivity category.[1] The network launched an AI platform called Lumina to help others benchmark and replicate successes, drawing on eight years of data from these leaders. This expansion reflects a global push amid economic volatility, where factories blend multiple technologies for resilience.

A Stark Global Contrast in Representation

Devens marked the sole North American addition, revealing U.S. underrepresentation in advanced manufacturing tech.[3] China dominated the new cohort with 14 sites, followed by India with three, while single entries came from Turkey, Azerbaijan, and Vietnam.

This distribution highlights how Asian manufacturers lead in deploying AI at scale, often achieving dramatic gains like 40-50% reductions in defects or lead times.[1]

Inside Devens: AI Tackles Pharma’s Toughest Challenges

The 89-acre Devens campus employs 1,700 people and handles everything from process development to commercial production of biologics and CAR-T cell therapies for hard-to-treat cancers.[3] Workers there re-engineer patient cells to target tumors, a process demanding precision amid natural variability in living materials. Traditional methods struggled with tight quality controls and scalability.

Leaders integrated over 30 AI and digital use cases, including predictive process monitoring, advanced analytics, and real-time decision tools.[4] Automation and modular suites now connect equipment for smarter orchestration. Results proved transformative: new product introduction timelines dropped 42%, production volumes rose more than 40%, and emissions fell over 40%.[1]

These gains stemmed from multidisciplinary teams empowered by data, allowing faster variability detection and continuous optimization. The site evolved as a blueprint, blending science with tech for resilient, sustainable output.

Why the U.S. Trails and What It Means

U.S. manufacturing lags in AI uptake, with supply chain and production functions in single digits for generative AI use, per McKinsey surveys.[5] Legacy equipment, skill gaps, and cautious investment slow progress, even as overall AI experimentation grows. Globally, lighthouses show AI can boost productivity by combining tools like machine learning with IoT.

For stakeholders, the implications loom large. Pharma firms like Bristol Myers Squibb gain faster drug delivery to patients, cutting costs and environmental impact. Workers benefit from upskilling in hybrid roles, though broader adoption could reshape factory jobs. U.S. policymakers and executives face pressure to bridge the gap, lest competitors erode market share.

Devens offers a roadmap: start with high-impact vertical applications, foster cross-functional collaboration, and scale via proven models. As AI evolves into cognitive networks, America’s manufacturing revival may hinge on emulating such outliers. The question remains whether more U.S. plants will follow suit before the divide widens further.